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DObjective: To evaluate the long-term results of aortic valve replacement (AVR) and mitral valve replacement
(MVR) with the Sorin Bicarbon prosthesis (SBP).
Methods: Five hundred seven patients (306 men, 201 women), mean age 62  10 years (range, 21-86 years),
received an SBP between 1994 and 2000; AVR was performed in 344 (67%) and MVR in 163 (33%). The main
concomitant procedure was coronary artery grafting in 79 patients (16%). Follow-up was 99% complete; mean
follow-up was 12.7 4.0 years with a cumulative duration of follow-up of 6475 patient-years in the entire group
(4348 patient-years for AVR and 2124 patient-years for MVR).
Results: Hospital mortality was 2.7% (AVR, 2.03%; MVR, 4.3%). There were 169 late deaths (AVR, 128;
MVR, 41). Actuarial survival at 17 years is 49.7%  5.3% for AVR and 62.0%  6.1% for MVR. At the
last follow-up, 310 survivors (199 AVR, 111 MVR) are in New York Heart Association functional class I or
II. At 17 years, actuarial freedom from valve-related deaths, embolism, and bleeding is 89.8%  4.8%,
85.8%  5.4%, and 96.2%  1.2% after AVR, and 91.9%  3.9%, 96.3%  1.8%, 95.0%  2.9% after
MVR. Reoperation was required in 5 patients with AVR (thrombosis in 4 and perivalvular leak in 1). Actuarial
freedom from reoperation is 98.1%  0.8% after AVR and 100% after MVR; freedom from endocarditis is
100% after AVR and 99.2%  0.7% after MVR. No cases of intrinsic structural valve failure were observed.
Conclusions: The SBP has shown excellent results in terms of clinical improvement and freedom from
valve-related complications, even up to 17 years after AVR and MVR. It therefore seems to be a safe option
whenever a mechanical prosthesis is needed. (J Thorac Cardiovasc Surg 2014;148:2039-44)Bileaflet prosthetic valves have been in clinical use for
more than 4 decades and have widespread acceptance as
mechanical cardiac valve substitutes; they are considered
hemodynamically superior to tilting disc valves.1-4 The
Sorin Bicarbon prosthesis (SBP) (Sorin Biomedica,
Saluggia, Italy) has been available since 1990 and has
shown good early and medium-term results.5-10 However,
long-term follow-up data are limited and may be derived
mainly from 1 multicenter study reporting a 15-year
follow-up of 1704 patients from 12 European centers.11 In
this article, we report on clinical evaluation of the SBP
based on the experience of a single center with a maximum
follow-up of more than 17 years.
MATERIALS AND METHODS
A retrospective evaluation of patients receiving an SBP at our institution
from 1994 to 2000 was performed. Patients who had undergone isolatede Section of Cardiac Surgery,a University Hospital, Pisa, Italy; and Division of
ac Surgery,b University of Verona, Verona, Italy.
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The Journal of Thoracic and Caraortic valve replacement (AVR) or isolated mitral valve replacement
(MVR) were considered; patients with double valve replacement or who
received an SBP in association with other types of prostheses were
excluded. This study was approved by our Institutional Ethical Committee
and informed consent to participate to the study and use of data was
obtained from all long-term survivors.
Valve Design
The SBP is a mechanical prosthesis with 2 leaflets made of pyrolitic
carbon with a curved profile. The leaflets are included in a housing of
titanium alloy which, together with the sewing ring, is coated with a layer
of carbon (Carbofilm). The leaflets, which open up to 80 from a 20
horizontal axis, move through an innovative rolling hinge mechanism,
which provides low turbulence, partitioning of the flow into 3 equivalent
bloodstreams, and a full washing effect through the cardiac cycle.12,13
Patient Characteristics
A total of 507 patients were reviewed (Table 1). There were 306 men
(60%) and 201 women (40%); the mean age was 62  10 years
(range, 21-86 years). AVR was performed in 344 patients (67%) and
MVR in 163 (33%). The predominant valve pathology was calcific
degeneration for AVR and rheumatic disease for MVR. Preoperatively,
most patients were in New York Heart Association (NYHA) functional
class II and III; mean NYHA class was 2.5  0.5 for AVR and 2.6  0.5
for MVR; 74%were in sinus rhythm and 26% in chronic atrial fibrillation.
Mean left ventricular ejection fraction was 52%  9%. Chronic renal
failure (serum creatinine >2.0 mmol/L) was present in 13 patients
(2.5%) and moderate or severe chronic obstructive pulmonary disease in
28 (5.5%). Mean logistic EuroSCORE (European System for Cardiac
Operative Risk Evaluation) was 5.1%  0.5% (range, 1.5%-35%) for
AVR and 6.7%  0.8% (range, 1.5%-38%) for MVR. Urgent surgerydiovascular Surgery c Volume 148, Number 5 2039
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
INR ¼ international normalized ratio
MVR ¼ mitral valve replacement
NYHA ¼ New York Heart Association
SBP ¼ Sorin Bicarbon prosthesis
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In 137 cases (27%), other procedures were associated with valve
replacement, mainly coronary artery bypass grafting (64 patients, 19%),
replacement of the ascending aorta (13 patients, 4%), and aortic annulus
enlargement (11 patients, 3%) during AVR and tricuspid annuloplasty
(22 patients, 13%) during MVR.
Surgical Technique
A uniform technique was used throughout the series. Operations were
performed through a median sternotomy; in patients undergoing reopera-
tion, the chest was entered through a repeat sternotomy. Cardiopulmonary
bypass was established with the ascending aorta and single or bicaval
venous cannulation with moderate systemic hypothermia (28-32C). The
heart was arrested with antegrade cold blood cardioplegia into the aortic
root or coronary ostia maintaining topical cooling throughout the proce-
dure; retrograde cardioplegia was only occasionally used. The left ventricle
was vented through the right upper pulmonary vein for AVR cases. Prosthe-
ses were implanted using 2/0 nonabsorbable sutures reinforced by Teflon
felts placed in a subannular position for AVR after careful annular debride-
ment from calcium deposits when present; for MVR, the posterior mitral
leaflet with its chordal attachments was completely or partially left in place
in all cases and Teflon pledgets were placed in a supraannular everting
position. Prostheses were mainly oriented with 1 hinge facing the interven-
tricular septum for AVR and in the antianatomic position for MVR. Distal
coronary anastomoses were always performed before valve replacement.
Prosthetic sizes are shown in Table 1. All patients were given subcutaneous
heparin starting from the first postoperative day. Sodium warfarin therapy
was started after extubation and removal of chest drains, usually on
postoperative day 2; when a target international normalized ratio (INR)
of 2.5 for AVR (range, 2-3) and 3 for MVR (range, 2.5-3.5) was reached,
heparin was suspended. No patient was routinely given antiplatelet drugs.
Data Acquisition and Follow-up
Baseline datawere retrieved fromour local database.After discharge, all
patients were entered in our follow-up protocol, which includes serial
clinical controls at 1, 3, 6, and 12months and then on a yearly basis. Patients
were encouraged to refer to our outpatient clinic for evaluation of clinical
status and valve performance and to discuss by direct interview all
possible postoperative complications, which were assessed according to
well-established guidelines.14 Those unable to come back to our hospital
were contacted by phone and additional information was obtained from
relatives or referring physicians when necessary. The follow-up of the cur-
rent serieswas closed inDecember 2012 andwas 99% completewith only 5
patients untraced. Cumulative duration of follow-up is 6475 patient-years in
the entire group, 4348 patient-years for AVR and 2124 patient-years for
MVR; mean follow-up is 12.7  4.0 years ranging from 0.2 to 17.7 years.
Statistical Analysis
Data are presented as means  standard deviation and as simple per-
centages. Overall survival and freedom from valve-related complications2040 The Journal of Thoracic and Cardiovascular Surwere determined by Kaplan-Meier actuarial analysis and expressed
as percentages of patients who were event free  standard error.
The linearized rate of postoperative complications was expressed as
%/patient-year. Statistical analysis was performed using commercially
available SPSS software, version 17.0 (SPSS, Inc., Chicago, Ill).RESULTS
Operative Mortality and Survival
The incidence of major postoperative complications is
listed in Table 2. There were 14 early deaths (<30 days)
with a cumulative operative mortality of 2.7%; mortality
was 2% (7 patients) for AVR and 4% (7 patients) for
MVR. Causes of hospital mortality were cardiac and
multiorgan failure in 10 patients and sepsis in 4 patients.
There were 169 late deaths, 128 after AVR and 41 after
MVR; of these, 22 were considered as valve-related, with
a linearized incidence of 0.34%  0.07%/patient-year;
these deaths were caused by embolism in 8 patients
(6 AVR and 2 MVR), hemorrhage in 5 (4 AVR and 1
MVR), prosthesis thrombosis in 3 (all AVR), endocarditis
in 1 MVR, periprosthetic leak in 1 MVR, and 4 sudden
unexpected deaths (3 MVR, 1 AVR). Actuarial survival is
81%  2% at 10 years and 50%  3% at 17 years
after AVR (Figure 1) and 83%  3% at 10 years and
62%  6% at 17 years after MVR (Figure 2). Actuarial
freedom from prosthesis-related deaths is 96%  2% at
10 years and 90%  5% at 17 years for AVR (Figure 1)
and 99%  1% at 10 years and 92%  4% at 17 years
for MVR (Figure 2). Of the 316 current survivors
reevaluated (202 AVR and 114 MVR), 172 are in NYHA
class I, 138 are in class II, and 6 are in class III; the mean
postoperative NYHA class is 1.4  0.6 for AVR
(P< .001) and 1.5  06 for MVR (P< .001). A total of
247 patients are in sinus rhythm (161 AVR and 86 MVR)
and 51 are in chronic atrial fibrillation (31 AVR and 20
MVR); 18 patients have a permanent pacemaker. The
mean INR value at last follow-up was 2.6  0.5 for AVR
patients and 2.7  0.4 for MVR patients.Embolism
A total of 22 embolic episodes were recorded with a
linearized incidence of 0.34%  0.07%/patient-year; 17
occurred after AVR (0.39%  0.09%/patient-year) and
5 after MVR (0.24%  0.11%/patient-year). The mean
age was 63  10 years for AVR patients and 64  8 years
for MVR patients; 1 of the AVR patients and 2 of the
MVR patients were in atrial fibrillation. A fatal cerebral
embolism occurred in 8 patients (6 AVR and 2 MVR) at a
mean time from operation of 9.7  4.5 years and with a
linearized incidence of 0.12%  0.04%/patient-year; of
the 14 patients with a nonfatal embolism, 5 had permanent
sequelae. Last mean INR available in patients with an
embolic event was 2.9  0.5 for AVR and 2.6  0.4 for
MVR.gery c November 2014
TABLE 1. Summary of clinical and surgical data
AVR (%) MVR (%) Total (%)
No. of patients 344 (67) 163 (33) 507 (100)
Gender
Male 237 (69) 68 (42) 306 (60)
Female 105 (31) 95 (58) 201 (40)
Mean age (y  SD) 62  10 62  9 62  10
Valvular lesion
Stenosis 102 (30) 39 (24) 141 (28)
Incompetence 85 (25) 75 (46) 160 (32)
Stenosis and incompetence 157 (45) 49 (30) 206 (40)
Valve pathology
Calcific degeneration 235 (68) 15 (9) 250 (49)
Rheumatic 62 (18) 112 (69) 174 (34)
Myxomatous degeneration 36 (10) 21 (14) 57 (11)
Endocarditis 2 (1) 3 (1) 5 (1)
Prosthetic dysfunction 9 (3) 9 (6) 18 (4)
Other — 3 (1) 3 (1)
NYHA class
II 169 (49) 65 (40) 234 (46)
III 175 (51) 97 (59) 272 (53)
IV — 1 (1) 1 (1)
Rhythm
Sinus 309 (89) 65 (40) 374 (74)
Atrial fibrillation 35 (10) 98 (60) 133 (26)
Pacemaker 5 (1) — 5 (1)
Renal failure 9 (3) 4 (2) 13 (3)
Chronic obstructive pulmonary
disease
21 (6) 7 (4) 28 (6)
EuroSCORE (%) 5.1  0.5 6.7  0.8 5.6  6.4
Associated procedures
Coronary artery bypass graft 64 (19) 15 (9) 79 (16)
Replacement ascending aorta 13 (4) — 13 (3)
Aortic annulus enlargement 11 (3) — 11 (3)
Tricuspid annuloplasty 12 (3) 22 (13) 34 (7)
Prosthetic size
19 mm 1 (1) — 1 (1)
21 mm 62 (18) — 62 (12)
23 mm 159 (46) — 159 (31)
25 mm 95 (28) 2 (1) 97 (19)
27 mm 23 (7) 59 (36) 82 (16)
29 mm 4 (1) 71 (44) 75 (15)
31 mm — 25 (15) 25 (5)
33 mm — 6 (4) 6 (1)
AVR, Aortic valve replacement; MVR, mitral valve replacement; SD, standard
deviation; NYHA, New York Heart Association; EuroSCORE, European System for
Cardiac Operative Risk Evaluation.




Six patients experienced prosthetic thrombosis at a
mean interval of 10  5 years from AVR with an inci-
dence of 0.09%  0.04%/patient-year; in this group, the
last available mean INR was 2.5  0.2. The mean age
was 65  8 years and 1 patient was in atrial fibrillation.
Four patients were reoperated and there were 3 deaths
because of multiorgan failure. No known case of pros-
thetic thrombosis occurred after MVR. Actuarial freedomThe Journal of Thoracic and Carfrom thromboembolism, including embolic episodes and
valve thrombosis, is 96%  1% at 10 years and 86%
 5% at 17 years for AVR patients and 98%  1% at
10 years and 96%  2% at 17 years for MVR patients
(Figure 3).
Hemorrhages
Anticoagulant-related hemorrhages were observed in
13 patients with a linearized incidence of 0.20% 
0.06%/patient-year. They involved 10 patients with AVR
(0.23%  0.07%/patient-year) and 3 with MVR (0.14%
 0.08%/patient-year); 5 patients (4 AVR and 1 MVR)
had a fatal hemorrhage. This complication occurred at a
mean time since operation of 9.1 5.3 years when the least
available mean INR was 2.5  0.3 for AVR patients and
2.6  0.4 for MVR patients. Actuarial freedom from
anticoagulant-related hemorrhages is 97%  1% at 10
years and 96%  1% at 17 years for AVR patients and
100% at 10 years and 95%  3% at 17 years for MVR
patients.
Perivalvular Leak
A periprosthetic leak was observed in 1 patient 3 years
after AVR giving an incidence of 0.02  0.02%/patient-
year; this patient died at reoperation in low output state.
Actuarial freedom from this complication is 99%  1%
at 10 and 17 years after AVR and 100% at 10 and 17 years
after MVR.
Endocarditis
One case of endocarditis was recorded 9 years after MVR
with a linearized incidence of 0.05%  0.05%/patient-
year. This patient died of sepsis without reoperation.
Actuarial freedom from endocarditis after AVR is 100%
at 10 and 17 years and after MVR is 99%  1% at
10 and 17 years, respectively.
Reoperation
Five patients required reoperation at a mean interval of
7  5 years from AVR giving an incidence of 0.11% 
0.05%/patient-year. Causes of reoperation were prosthetic
thrombosis in 4 and periprosthetic leak in 1. No patient
with MVR underwent reoperation and no cases of intrinsic
SBP failure were observed. Actuarial freedom from
reoperation is 99%  1% at 10 years and 98%  1% at
17 years for AVR patients and 100% at 10 and 17 years
for MVR patients.
Valve-Related Complications
Overall, valve-related complications occurred in 47 pa-
tients with an incidence of 0.73%  0.11%/patient-year
in the entire series; 35 (0.80%  0.14%/patient-year)
were observed after AVR and 12 after MVR (0.56% 
0.16%/patient-year). Causes were as follows: embolismdiovascular Surgery c Volume 148, Number 5 2041
TABLE 2. Linearized incidence of major postoperative complications
AVR MVR Total
n % patient-years n % patient-years n % patient-years
Late deaths 128 2.94  0.26 41 1.93  0.30 169 2.61  0.20
Valve related 15 0.34  0.09 7 0.33  0.12 22 0.34  0.07
Embolism 17 0.39  0.09 5 0.24  0.11 22 0.34  0.07
Fatal 6 0.14  0.06 2 0.09  0.07 8 0.12  0.04
Valve thrombosis 6 0.14  0.06 — — 6 0.09  0.04
Fatal 3 0.07  0.04 — — 3 0.05  0.03
Hemorrhages 10 0.23  0.07 3 0.14  0.08 13 0.20  0.06
Fatal 4 0.09  0.05 1 0.05  0.05 5 0.08  0.04
Periprosthetic leak 1 0.02  0.02 — — 1 0.02  0.02
Endocarditis — — 1 0.05  0.05 1 0.02  0.02
Reoperation 5 0.11  0.05 — — 5 0.08  0.03
Overall valve-related complications 35 0.80  0.14 12 0.56  0.16 47 0.73  011
AVR, Aortic valve replacement; MVR, mitral valve replacement.
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(all AVR), anticoagulant-related hemorrhages in 13
(10 AVR and 3 MVR), sudden unexpected death in 4
(1 AVR and 3 MVR), endocarditis (1 MVR), and peri-
prosthetic leak (1 AVR). Actuarial freedom from overall
prosthesis-related complications is 93%  2% at 10 years
and 82%  5% at 17 years after AVR and 96%  2% at
10 years and 86%  5% at 17 years after MVR.
DISCUSSION
Evaluation of the performance of any cardiac valve
substitute requires continuous patient monitoring and
follow-up to obtain meaningful data, especially on the
incidence of valve-related complications. This applies
particularly to recipients of mechanical valves, which are
significantly more prone to specific complications such as
valve thrombosis and systemic embolic accidents than their
biological prostheses counterparts. For this reason, data
collected on extended follow-up of patients receiving
mechanical prostheses seem of paramount importance toFIGURE 1. Actuarial survival and freedom from valve-related deaths
after aortic valve replacement with the Sorin Bicarbon prosthesis. Numbers
on the horizontal axis indicate patients at risk at each time interval.
2042 The Journal of Thoracic and Cardiovascular Surassess the overall performance of any given device in the
long term. The SBP has been available for clinical use for
more than 3 decades but, despite the high number of these
valves implanted worldwide, data on very long-term
follow-up are scarce. The recent update of a European
multicenter study11 presented clinical outcomes of SBP
recipients at 15 years, indicating that the SBP continues
to perform satisfactorily even beyond the 10-year limit
reached in other studies.9,15
This article presents our experience with the SBP from a
single center, thus eliminating the potential bias of methods
and data collection from different institutions and therefore
providing more reliable information derived from an
extended follow-up; in our series, the mean follow-up was
more than 12 years for both AVR and MVR patients with
a maximum follow-up of more than 17 years. Operative
mortality was low, less than 3% in the entire series, despite
a high mean age and almost 30% of patients had an
associated procedure; furthermore, no early deaths were
valve related. Late survival was also extremely gratifying,FIGURE 2. Actuarial survival and freedom from valve-related deaths af-
ter mitral valve replacement with the Sorin Bicarbon prosthesis. Numbers
on the horizontal axis indicate patients at risk at each time interval.
gery c November 2014
FIGURE 3. Actuarial freedom from thromboembolic episodes after aortic
(AVR) and mitral (MVR) valve replacement with the Sorin Bicarbon
prosthesis. Numbers on the horizontal axis indicate patients at risk at
each time interval.
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others8-11 and with a clinical benefit in the long-term
survivors as shown by the significant improvement in
functional class; furthermore, late survival seems to be
superior to that observed with other bileaflet prostheses
in younger patient populations.16-18 Late mortality is
usually considered to be independent of the type of
prosthesis used, and is mostly influenced by patient
selection, preoperative clinical status, and associated
comorbidities.19,20 The low incidence of prosthesis-
related late deaths with a linearized incidence of 0.34%
 0.07%/patient-year and an actuarial freedom at 17 years
of 90% for AVR and 92% for MVR is nevertheless
noteworthy.
Thromboembolic complications are a continuous concern
in recipients of mechanical prostheses. In the present series,
however, a low incidence of embolic events was observed
with a linearized incidence of 0.39%  0.09%/patient-
years after AVR and 0.24%  0.11%/patient-years after
MVR with an actuarial freedom from thromboembolism,
including valve thrombosis, of 86% and 96%, respectively,
after AVR and MVR at 17 years, indicating that the
innovative changes incorporated into the SBP design,
improving transprosthetic flow and reducing turbulence,
might positively influence its thrombogenicity. These
figures compare favorably with those reported for the
same device at shorter follow-up intervals8-11 and are
similar or even superior to those observed with other
bileaflet prostheses16-18,21-23; according to Ikonomidis and
colleagues,17 the incidence of reported thromboembolism
with the St Jude Medical prosthesis ranges from 0.8% to
3.5%/patient-year. A low rate of thromboembolism has
also been reported with the On-X bileaflet mechanical
prosthesis. Chan and colleagues24 observed an incidence
of thromboembolism of 0.94%/patient-year after AVR and
0.72%/patient-year after MVR; Chambers and colleagues25The Journal of Thoracic and Carreported that this complication occurred with an incidence
of 0.6%/patient-year and 1.0%/patient-year late after
AVR and MVR, respectively. As also noted by others,17
we have observed a disturbing incidence (6 episodes) of
SBP thrombosis in AVR patients; this complication did not
occur in MVR patients. We do not have a clear explanation
for such outcomes, which are contrary to what has been
reported in the literature. In our long-term survivors, we
collected data on INR and found that the mean values
were within the desired limits at the last follow-up, as
currently suggested.26 Embolic episodes and valve
thrombosis occurred despite an INR within the planned
target values; this apparent paradox, as observed by others,10
is difficult to explain but the role of other factors that could
have contributed to such events must be considered. The
presence of an enlarged left atrium or a dilated left ventricle
has not been thoroughly analyzed, and the impact of other
specific patient-related factors, as suggested by Butchart
and colleagues,27 could not be assessed retrospectively.
Thus, the fact that INR values were within the target range
and that most patients were in sinus rhythm at the time of
the event makes the unusual incidence of prosthetic
thrombosis after AVR more difficult to understand. It must
be also recognized that maintenance of stable INR values
is often difficult to achieve and even mild variations in the
intensity of anticoagulation are almost impossible to predict,
thus limiting the relevance of our data on INR values.
Mechanical valve recipients require life-long strict and
carefully controlled warfarin treatment but, despite this,
anticoagulant-related hemorrhages are still a major problem
in these patients. Although this complication in our patient
subset was low, with an actuarial freedom at 17 years of
more than 95% in both groups, the occurrence of fatal
bleeding, albeit limited, is still disturbing, indicating that
the optimal intensity of oral anticoagulant therapy in
patients with mechanical prostheses is still a matter of
debate.26,28-30
We have also found that other major postoperative
complications, such as endocarditis and periprosthetic,
leak are extremely uncommon after AVR and MVR with
the SBP; moreover, no cases of structural failure were
recorded, as also observed by others with the SBP as well
as other bileaflet valves,10,11,16,21 thus confirming that the
current generation of mechanical prostheses provides
valve substitutes resistant to wear and mechanical stresses
over time. In the present experience, the need for
reoperation for all causes was also extremely low, with an
incidence of 0.08%/patient-year, similar to other reports
on various models of mechanical prostheses.11,17,21,22
The major limitation of this paper is that it is an
observational retrospective study; however, it has the
advantage of reporting data from a single center on a
large number of patients, accurately reevaluated and with
almost complete follow-up with few patients untraced.diovascular Surgery c Volume 148, Number 5 2043
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performance of the SBP in the long term. Furthermore,
we have not provided information on the hemodynamic
behavior of this prosthesis. Previous reports have indicated
that the SBP has an excellent hemodynamic performance
both in vitro and in vivo with lower transvalvular gradients
compared with other similar prostheses.31-33 Data from our
group have already shown that, for the small sizes, the SBP
is associated with low gradients, significant regression of
left ventricular mass after AVR, and, more importantly,
the absence of prosthesis-patient mismatch.34 Another issue
that is not considered in this report concerns the occurrence
of hemolysis. Subclinical hemolysis is frequently observed
in normally functioning mechanical prostheses; this
problem was addressed previously and it was shown that
in patients with an SBP, the incidence of hemolysis was
extremely low and even less frequent than observed with
other bileaflet valves.11,35
In conclusion, our results indicate that the SBP continues
to show an excellent overall performance up to 17 years
postoperatively, as indicated by the significant clinical
improvement achieved, the low incidence of postoperative
adverse events, and a gratifying freedom from major
valve-related complications in the long term. Therefore,
based on the present experience, we conclude that the
SBP remains a reliable and valid option whenever a
mechanical prosthesis is indicated for both AVR and MVR.References
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